In vitro microbial efficacy of sulbactomax: A novel fixed dose combination of ceftriaxone sulbactam and ceftriaxone alone

Current Drug Therapy

Volumn 4, Issue 1, 2009, Pages 73-77

  Shrivastava, Sanjay Mohan ^a   Saurabh, Sandeep ^a   Rai, Dharmendra ^a   Dwivedi, Vivek Kumar ^a   Chaudhary, Manu ^a  

^a Venus Medicine Research Centre   (India)

Author keywords

Ceftriaxone; MIC; Sulbactomax; Time kill curve

Indexed keywords

ANTIBIOTIC AGENT; CEFTRIAXONE; SULBACTAM; SULBACTOMAX; UNCLASSIFIED DRUG;

ANTIBIOTIC SENSITIVITY; BACILLUS SUBTILIS; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DRUG EFFICACY; ESCHERICHIA COLI; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; STAPHYLOCOCCUS AUREUS;

EID: 65349092895     PISSN: 15748855     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488509787081840     Document Type: Review

References (19)

1. Donowitz GR, Masndell GL. β lactam antibiotics. (second of two parts). N Engl J Med 1998; 310: 490.
2. Philippon A, Labia R, Jacoby G. Extended spectrum β-lactamases. Antimicrob Agents Chemother 1989; 33: 1131.
3. Bush K. Excitement in the β-lactamase arena, J Antimicrobial Chemother 1998; 24: 831.
4. Brinas L, Lantero M, de Diego I, Alvarez M, Zarazaga M, Torres C. Mechanisms of resistance to expanded-spectrum cephalosporins in Escherichia coli isolates recovered in a Spanish hospital. J Antimicrob Chemother 2005; 56(6): 1107-10.
5. Rolinson GN. Evolution of β-Lactamase inhibitors. Surg Gynaecol Obstet 1991; 172(suppl): 11-16.
6. Moellering RC Jr. Meeting the challenges of b-lactamases. J Antimicrob Chemother 1993; 31(suppl A): 1-8.
7. Levy SB, Marshall B, Schlucderberg S. High frequency of antimicrobial resistance in human fecal flora. Antimicrob Agents Chemother 1988; 31: 1801-6.
8. Barry AL, Jones RN. Criteria for disk susceptibility tests and quality control guidelines for the cefoperazone-sulbactam combination. J Clin Microbiol 1988; 26(1): 13-17.
9. Amsterdam D. Susceptibility testing of antibiotics in liquid media, In: Lorian V. (Ed.), Antibiotics in laboratory medicine, 4th ed. The Williams & Wilkins Co., Baltimore, Md. 1996; pp. 52-111.
10. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically,4th ed. Approved standard M7-A4. National Committee for Clinical Laboratory Standards, Wayne, Pa 1997.
11. Pearson RD, Steigbigel RT, Davis HT, Chapmann SW. Method for reliable determination of minimal lethal antibiotic concentrations. Antimicrob. Agents Chemother 1980; 18: 699-708.
12. Clarke AM, Zemcov SJV, Wright JM. HR - 810 and BMY -28142 two new cephalosporins with broad spectrum activity: an in-vitro comparison with other beta-lactam antibiotics. J Antimicrob Chemother 1985; 15: 305-310.
13. Kessler RE, Bies M, Buck RE, et al. Comparison of a new cephalosporin, BMY 28142, with other broad - spectrum β-lactam antibiotics. Antimicrob Agents Chemother 1985; 27: 207-216.
14. Tsuji A, Maniatis A, Bertram MA, Young LS. In vitro activity of BMY 28142 in comparison with those of other β-lactam anti microbial agents. Antimicrob Agents Chemother 1985; 27: 515-519.
15. Shrivastava SM, Saurabh S, Rai D, Chaudhary M. Comparative evaluation of microbial efficacy of Potentox, a fixed dose combination of cefepime amikacin with cefepime and amkacin alone. J Natcon 2008; 20 (1): 121-126
16. Phelps DJ, Carlton DD, Farrell CA, Kessler RE. Affinity of cephalosporins for β-lactamases as a factor in antibacterial efficacy. Antimicrob Agents Chemother 1986; 29: 845-84.
17. Corbella X, Ariza J, Ardanuy C, et al. Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by multiresistant Acinetobacter baumannii. J Antimicrob Chemother 1988; 42: 793-802.
18. Higgins PG, Wisplinghoff H, Stefanik D, Seifert H. In vitro activities of the β-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains. Antimicrob Agents Chemother 2004; 48: 1586-1592.
19. Levin AS. Multiresistant Acinetobacter infections: a role for sulbactam combinations in overcoming an emerging worldwide problem. Clin Microbiol Infect 2002; 8: 144-153.